Graft-Versus-Host Disease Excellence Forum

Graft-Versus-Host Disease

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Efficacy of Omidubicel vs Standard Umbilical Cord Blood Transplantation for Patients With GVHD

03/09/2022

Mitchell E. Horwitz, MD, discusses results from a phase 3 trial evaluating the efficacy of omidubicel compared to standard umbilical cord blood transplantation for patients with GVHD.

Mitchell E. Horwitz, MD,...

03/09/2022

Oncology

Videos

GVHD Outcomes of Busulfan Plus Fludarabine for Older Patients With Hematologic Malignancies

03/03/2022

Uday R Popat, MD, overviews the long-term disease outcomes from a phase 2 prospective clinical trial on myeloablative fractionated busulfan with fludarabine in older patients with hematologic malignancies.

Uday R Popat, MD, overviews the...

03/03/2022

Oncology

Interview

Post-Transplantation Cyclophosphamide Plus Sirolimus Associated With Lower Risk of Chronic GVHD

02/24/2022

Madiha Iqbal, MD, MBBS, spoke on findings from a study evaluating post-transplantation cyclophosphamide plus sirolimus and how it is associated with a lower risk of chronic GVHD.

Madiha Iqbal, MD, MBBS, spoke on...

02/24/2022

Oncology

Videos

Dr Iqbal Highlights Calcineurin Inhibitor Free GVHD Prophylaxis for Patients Undergoing Allo-HCT

02/22/2022

Madiha Iqbal, MD, MBBS, discusses calcineurin inhibitor free GVHD prophylaxis for patients undergoing matched-related and matched-unrelated donor allogeneic HCT.

Madiha Iqbal, MD, MBBS,...

02/22/2022

Oncology

Videos

Orca-T Demonstrates Reduced Instances of GVHD for Hematologic Malignancies

01/24/2022

Dr Meyer on how Orca-T, an investigational cell therapy, led to high GVHD- and relapse-free survival following myeloablative conditioning for hematologic malignancies, presented at ASH 2021.

Dr Meyer on how Orca-T, an...

01/24/2022

Oncology

Videos

Dr Hamilton Talks Tacrolimus Plus Mexotrexate With or Without Mycophenolate Mofetil for GVHD

01/20/2022

Betty Hamilton, MD, shares results from a trial comparing tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate and mycophenolate mofetil for the prevention of GVHD after allogeneic HCT, presented at ASH 2021.

Betty Hamilton, MD, shares...

01/20/2022

Oncology

Videos

Human Chorionic Gonadotropin/Epidermal Growth Factor as Treatment for aGVHD

01/13/2022

Shernan Holtan, MD, provides overview of a phase 2 study on human chorionic gonadotropin and epidermal growth factor as treatment for patients with aGVHD. These data were presented at ASH 2021.

Shernan Holtan, MD, provides...

01/13/2022

Oncology

Videos

Dr Lazaryan Discusses ROCKstar Study Results for cGVHD

08/05/2021

Aleksandr Lazaryan, MD, MPH, PhD, discusses the phase 2b ROCKstar study of belumosudil in patients with cGVHD after ≥2 prior lines of therapy.

Aleksandr Lazaryan, MD, MPH,...

08/05/2021

Oncology

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

Videos

Aleksandr Lazaryan, MD, Discusses Belumosudil as Effective Therapy for cGVHD

06/21/2021

Dr Lazaryan discusses a phase 2a clinical trial of belumosudil in patients with pretreated cGVHD.

Dr Lazaryan discusses a phase 2a...

06/21/2021

Oncology

Recent News

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine ;

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

News

ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD

05/10/2021

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.

Belumosudil produces high...

05/10/2021

Oncology

News

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

06/23/2020

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

In a phase 2 clinical trial,...

06/23/2020

Oncology

News

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

05/13/2020

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Ruxolitinib significantly...

05/13/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology